Cibus (CBUS) Projected to Post Earnings on Tuesday

Cibus (NASDAQ:CBUS) is anticipated to post its Q4 2025 results after the market closes on Tuesday, March 17th. Analysts expect Cibus to post earnings of ($0.43) per share and revenue of $1.6440 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:30 PM ET.

Cibus Stock Performance

Shares of CBUS opened at $3.68 on Tuesday. The business’s fifty day moving average price is $2.39 and its two-hundred day moving average price is $1.78. The firm has a market capitalization of $199.75 million, a price-to-earnings ratio of -1.13 and a beta of 1.62. Cibus has a 52 week low of $1.09 and a 52 week high of $3.80.

Institutional Trading of Cibus

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Cibus in the 2nd quarter valued at $207,000. Corient Private Wealth LLC acquired a new stake in shares of Cibus during the fourth quarter worth $145,000. Squarepoint Ops LLC acquired a new stake in shares of Cibus during the third quarter worth $62,000. AQR Capital Management LLC bought a new stake in Cibus in the first quarter valued at about $73,000. Finally, Renaissance Technologies LLC lifted its stake in Cibus by 74.4% in the fourth quarter. Renaissance Technologies LLC now owns 69,400 shares of the company’s stock valued at $121,000 after buying an additional 29,600 shares during the period. Institutional investors own 33.81% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CBUS. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price target on shares of Cibus in a research note on Monday, December 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $20.00.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.